These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Flockhart RJ; Armstrong JL; Reynolds NJ; Lovat PE Br J Cancer; 2009 Oct; 101(8):1448-55. PubMed ID: 19724275 [TBL] [Abstract][Full Text] [Related]
4. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Thomas NE Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964 [TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy in Advanced Melanoma With Rare Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757 [TBL] [Abstract][Full Text] [Related]
6. TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro. Delyon J; Vallet A; Bernard-Cacciarella M; Kuzniak I; Reger de Moura C; Louveau B; Jouenne F; Mourah S; Lebbé C; Dumaz N Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296851 [TBL] [Abstract][Full Text] [Related]
7. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830 [TBL] [Abstract][Full Text] [Related]
8. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307 [TBL] [Abstract][Full Text] [Related]
9. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Reid AL; Freeman JB; Millward M; Ziman M; Gray ES Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300 [TBL] [Abstract][Full Text] [Related]
10. Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines. Dorris ER; Blackshields G; Sommerville G; Alhashemi M; Dias A; McEneaney V; Smyth P; O'Leary JJ; Sheils O Cancer Biol Ther; 2016 May; 17(5):526-42. PubMed ID: 26828826 [TBL] [Abstract][Full Text] [Related]
11. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Liu D; Liu X; Xing M Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969 [TBL] [Abstract][Full Text] [Related]
12. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. Rose AAN Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693 [TBL] [Abstract][Full Text] [Related]
13. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors. Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351 [TBL] [Abstract][Full Text] [Related]